MMSI:NSD-Merit Medical Systems Inc (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 101.68

Change

-2.56 (-2.46)%

Market Cap

USD 5.76B

Volume

0.33M

Analyst Target

USD 51.38
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. It also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate structures; gastroenterology products, such as covered esophageal stents, syringe and gauges, and balloon dilators; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ISRG Intuitive Surgical Inc

-0.38 (-0.07%)

USD 180.35B
COO The Cooper Companies, Inc. Com..

-0.12 (-0.12%)

USD 20.95B
HOLX Hologic Inc

-0.58 (-0.73%)

USD 19.12B
ALGN Align Technology Inc

-4.06 (-1.85%)

USD 16.05B
RGEN Repligen Corporation

+1.88 (+1.27%)

USD 7.52B
XRAY Dentsply Sirona Inc

-0.42 (-2.36%)

USD 4.76B
ICUI ICU Medical Inc

-3.20 (-1.80%)

USD 4.17B
AZTA Azenta Inc

-1.48 (-3.22%)

USD 2.25B
LMAT LeMaitre Vascular Inc

-0.69 (-0.67%)

USD 2.00B
ATRC AtriCure Inc

-0.43 (-1.17%)

USD 1.76B

ETFs Containing MMSI

HLTH:AU VanEck Global Healthcare .. 2.09 % 0.00 %

-0.09 (-0.78%)

USD 0.06B
PSCH Invesco S&P SmallCap Heal.. 0.00 % 0.29 %

-0.51 (-0.78%)

USD 0.18B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 33.86% 76% C+ 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.86% 76% C+ 82% B
Trailing 12 Months  
Capital Gain 40.95% 72% C 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.95% 72% C 77% C+
Trailing 5 Years  
Capital Gain 284.57% 96% N/A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 284.57% 96% N/A 94% A
Average Annual (5 Year Horizon)  
Capital Gain 20.01% 63% D 73% C
Dividend Return 20.01% 63% D 73% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 31.40% 74% C 60% D-
Risk Adjusted Return 63.73% 98% N/A 85% B
Market Capitalization 5.76B 87% B+ 89% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector